Rapid Anti-Depressant Response Produced by Low Dose Treatment with Anti-Muscarinic Drugs


Available for licensing are new methods of rapidly treating depression. The drugs currently used to treat depression work by increasing the activity at serotonin, norepinephrine and perhaps dopamine receptors in the CNS. However these drugs are effective in only 60-70% of patients, require 3-4 weeks of treatment before clinical improvement and have many side effects. These inventors have shown that in human patients, the administration of anti-muscarinic agents produces a rapid, prolonged alleviation of depressive symptoms. Beginning the day following administration of the anti-muscarinic agent, a majority of patients show significant improvements in mood, anxiety, sleep and other depressive symptoms that last days or weeks. The very slow dissociation of some muscarinic agents from their receptors may account for the prolonged therapeutic effects.

Inventors:

Wayne Drevets (NIMH)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 8,859,585 issued 2014-10-14
U.S. Pat: 9,707,220 issued 2017-07-18
US Application No. 14/478,442

Licensing Contact:
Jennifer Wong, M.S.
Email: jennifer.wong2@nih.gov
Phone: 301-480-4821

OTT Reference No: E-175-2004-0
Updated: May 24, 2016